PA
CYTK icon

Parallel Advisors’s Cytokinetics CYTK Stock Holding History

Parallel Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Buy
1,256
+337
+37% +$24.2K ﹤0.01% 1664
2026
Q1 		$60.6K Buy
919
+85
+10% +$5.4K ﹤0.01% 1888
2025
Q4 		$53K Buy
834
+17
+2% +$1.06K ﹤0.01% 1822
2025
Q3 		$44.9K Buy
817
+32
+4% +$1.32K ﹤0.01% 1843
2025
Q2 		$25.9K Sell
785
-314
-29% -$10.9K ﹤0.01% 2071
2025
Q1 		$44.2K Buy
1,099
+916
+501% +$42.1K ﹤0.01% 1708
2024
Q4 		$8.61K Sell
183
-229
-56% -$11.9K ﹤0.01% 2455
2024
Q3 		$21.8K Sell
412
-67
-14% -$3.73K ﹤0.01% 2059
2024
Q2 		$26K Buy
479
+144
+43% +$8.69K ﹤0.01% 1839
2024
Q1 		$23.5K Buy
335
+3
+0.9% +$232 ﹤0.01% 1895
2023
Q4 		$27.7K Buy
332
+43
+15% +$1.56K ﹤0.01% 1745
2023
Q3 		$8.51K Buy
289
+276
+2,123% +$9.19K ﹤0.01% 2281
2023
Q2 		$424 Buy
+13
New +$481 ﹤0.01% 3127
2023
Q1 		– Sell
-10
Closed -$458 – 3434
2022
Q4 		$458 Buy
+10
New +$430 ﹤0.01% 3046
2022
Q2 		– Sell
-7
Closed – – 3058
2022
Q1 		$0 Buy
+7
New +$249 ﹤0.01% 3024
2020
Q2 		– Sell
-48
Closed – – 2486
2020
Q1 		$0 Buy
+48
New +$612 ﹤0.01% 2427
2017
Q4 		– Sell
-1,200
Closed -$14K – 2086
2017
Q3 		$14K Sell
1,200
-500
-29% -$6.83K ﹤0.01% 1139
2017
Q2 		$24K Hold
1,700
– – ﹤0.01% 937
2017
Q1 		$27K Sell
1,700
-1,000
-37% -$11.7K 0.01% 844
2016
Q4 		$33K Buy
+2,700
New +$28.7K 0.01% 694

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parallel Advisors's CYTK Position: Q2 2026 in Review

Parallel Advisors increased its Cytokinetics (CYTK) stake by 37% in Q2 2026, buying an estimated $24.2K and bringing the position to 1,256 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Parallel Advisors first reported a position in CYTK in Q4 2016 and has held it in 20 quarters since. 329 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Parallel Advisors held 1,256 shares of Cytokinetics worth $107K as of Q2 2026.
  • Parallel Advisors bought 337 Cytokinetics shares in Q2 2026, an estimated $24.2K.
  • Cytokinetics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1664 holding.
  • Parallel Advisors first reported a position in Cytokinetics in Q4 2016 and has held it in 20 quarters since.
  • 329 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.